Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

India Globalization Capital Inc (NY: IGC )

0.4731 -0.0769 (-13.98%)
Streaming Delayed Price Updated: 11:42 AM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 140,545
Open 0.4613
Bid (Size) 0.4651 (1)
Ask (Size) 0.4732 (2)
Prev. Close 0.5500
Today's Range 0.4500 - 0.4875
52wk Range 0.2501 - 0.9099
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
From IGC Pharma, Inc.
Via Business Wire

Performance

YTD
+71.41%
+71.41%
1 Month
-3.33%
-3.33%
3 Month
+18.27%
+18.27%
6 Month
+58.39%
+58.39%
1 Year
+47.84%
+47.84%

More News

Read More
Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected
Via Benzinga
Topics Cannabis Regulatory Compliance
Exposures Cannabis Legal Regulatory
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Publication of Key Study in European Journal
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
From IGC Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
From IGC Pharma Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Management Hosting Meetings at Upcoming BIO International Convention 2024
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma to Attend BIO International Convention 2024
From IGC Pharma Inc.
Via Business Wire
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
Via News Direct
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
Via TheNewswire.com
Topics Cannabis
Exposures Cannabis Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Cannabis
Exposures Artificial Intelligence Cannabis
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Via Benzinga
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
From IGC Pharma, Inc.
Via Business Wire
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Via Benzinga
BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
IGC Pharma Adds Advisor in Artificial Intelligence
From IGC Pharma, Inc.
Via Business Wire
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.